Equities analysts expect that Imperva Inc (NASDAQ:IMPV) will post $91.18 million in sales for the current quarter, Zacks reports. Seven analysts have made estimates for Imperva’s earnings. The highest sales estimate is $92.00 million and the lowest is $90.48 million. Imperva reported sales of $78.40 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.3%. The firm is expected to issue its next earnings report after the market closes on Thursday, February 8th.
According to Zacks, analysts expect that Imperva will report full year sales of $91.18 million for the current year, with estimates ranging from $321.00 million to $322.64 million. For the next fiscal year, analysts expect that the company will post sales of $377.49 million per share, with estimates ranging from $372.00 million to $383.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Imperva.
Imperva (NASDAQ:IMPV) last announced its quarterly earnings data on Wednesday, November 8th. The software maker reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.11. The firm had revenue of $83.89 million during the quarter, compared to the consensus estimate of $83.79 million. Imperva had a net margin of 3.04% and a negative return on equity of 8.52%. The firm’s revenue was up 22.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.08 earnings per share.
Shares of Imperva (NASDAQ IMPV) traded up $0.30 during trading hours on Monday, reaching $44.20. 254,200 shares of the company were exchanged, compared to its average volume of 331,508. The firm has a market capitalization of $1,500.00, a P/E ratio of 163.70 and a beta of 1.78. Imperva has a 1 year low of $37.17 and a 1 year high of $52.40.
Several institutional investors and hedge funds have recently made changes to their positions in IMPV. Schwab Charles Investment Management Inc. lifted its holdings in shares of Imperva by 10.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 131,762 shares of the software maker’s stock valued at $6,305,000 after acquiring an additional 12,287 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Imperva by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 136,025 shares of the software maker’s stock valued at $6,509,000 after acquiring an additional 10,627 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Imperva by 27.2% during the 2nd quarter. Legal & General Group Plc now owns 13,545 shares of the software maker’s stock valued at $649,000 after acquiring an additional 2,894 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Imperva during the 2nd quarter valued at $1,434,000. Finally, Principal Financial Group Inc. acquired a new position in shares of Imperva during the 2nd quarter valued at $223,000. Institutional investors own 96.83% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/22/imperva-inc-impv-expected-to-post-quarterly-sales-of-91-18-million.html.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.